Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Syndax Pharmaceuticals
business
Nothing else this week.
-
Incyte
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireSyndax Reports Second Quarter 2025 Financial Results and Provides Business Update – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo